News - Heavy weight! Sanofi invests 1 billion euros to build a new insulin production base in Beijing, breaking the ice in biopharmaceuticals under the China Europe trade tensions!

4

year

Search This Supplers Products:fermentation bioreactorsbenchtop bioreactorslaboratory bioreactorsdisposable bioreactorsairlift fermentorsbioprocess equipment

home categories store home newsAritcals & News

Heavy weight! Sanofi invests 1 billion euros to build a new insulin production base in Beijing, breaking the ice in biopharmaceuticals under the China Europe trade tensions!

time2024/12/11

: Frederick Uday, Chairman of the Board of Directors of Sanofi Group, stated that the company has full confidence in the long-term development of the Chinese market.

bioreactor industrial

Against the backdrop of tense trade relations between China and Europe, France's largest healthcare company, Sanofi, announced a major investment agreement in China, with an investment amount of up to 1 billion euros.

This investment will establish a new production and manufacturing base in Yizhuang, Beijing, marking Sanofi's fourth production and supply base in China, and also the largest single investment in the company's history in China.

This measure will greatly improve the local production capacity of insulin and meet the growing demand of Chinese patients with diabetes.

Frederick Uday, Chairman of the Board of Directors of Sanofi Group, stated that the company has full confidence in the long-term development of the Chinese market.

He emphasized that the Chinese government's opening-up policy, encouraging innovation environment, and creating a favorable business environment for foreign-funded enterprises have provided strong confidence for Sanofi to deeply participate in China's economic development.

Sanofi hopes to contribute to the high-quality development of China's pharmaceutical and health industry by expanding its production and supply layout, strengthening cooperation with China's local industrial chain.

2 gallon glass fermenter

The latest statistics show that there are more than 140 million adults with diabetes in China, and the prevalence rate of adult diabetes is about 11.9%, and this number is still rising.

Sanofi's new production base will work together with production bases in Beijing, Shenzhen, and Hangzhou to ensure production capacity in China and meet the daily medication needs of patients in the Chinese and Asian markets.

Sanofi's business layout in China is extensive, including 12 offices, 3 production bases, and 4 research and development bases, covering multiple fields such as pharmaceuticals, human vaccines, and consumer healthcare.

Sanofi's Beijing production base in Beijing Economic and Technological Development Zone has become Sanofi's largest insulin injection production base in the Asia Pacific region, with products covering diabetes, cardiovascular, medical and tumor fields.

Recently, China and Europe are engaged in tense negotiations over issues such as export tariffs on electric vehicles, and the detention of Wang Lei, the CEO of British pharmaceutical giant AstraZeneca in China, has also given Western media new hype.

However, the insurance fraud case that Wang Lei may be involved in does not seem to have a widespread impact on foreign pharmaceutical companies.

In early November, Pfizer China President Peng Zhenke announced the "Pfizer China 2030 Strategy", which aims to accelerate the introduction of innovative drugs into the Chinese market and is expected to invest $1 billion in the next five years to implement the strategy.

The relevant person in charge of Beijing Economic and Technological Development Zone stated that in order to attract more multinational pharmaceutical companies to layout in Yizhuang, Beijing, the development zone uses international exhibitions as a window to transform industrial advantages into cooperation opportunities.

Recently, global leading pharmaceutical companies such as Eli Lilly and Pfizer have announced the establishment of new research and innovation institutions in Yizhuang, Beijing.

Yizhuang will continue to create an optimized business environment, create an open and inclusive industrial ecology, support multinational pharmaceutical companies to choose Beijing and invest in Yizhuang, and jointly draw a new blueprint for the development of the pharmaceutical and health industry.